Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
old*, there have been many posters on this MB that have advocated the same thing for years in different terms before this guy showed up with his "AI" generated type postings.
Ya not much interest . .. look at INMB … I was in and out .. pitched my tent back in Avxl for Rett readout . Missling did me no favour .. INMB with a 1B trial MC similar to Avxl .. hard to believe missling has screwed this up to the degree he has .. like what does the 40 employees do ?
I rarely post these days, but this post by Gary makes more sense than any I've read this year. For God's sake we're dealing with 100% terminal diseases here - let's initiate some treatment!
mrp, your analysis, please?
Talk about low volume. 40 minutes into normal hours trade day and 60K shares traded hands.
John k9uwa
How much of the ALL IN inheritance is left from $20+?
“Anavex 3-71 can treat those people that currently have schizophrenia.”
Correction: Anavex 3-71 may be able to treat those people that (it’s actually who, not that) currently have schizophrenia.
The purpose of clinical trials is to demonstrate safety and efficacy in humans. Until that time comes, no one can claim with certainty that Anavex 3-71 or any other drug candidate can treat any condition. You know this as well as anyone.
You have it completely wrong. Nobody here is against novel treatments that could help people like your mom. The frustration here is that Anavex has a potential treatment that is being delayed/derailed by a CEO whose gross incompetence is a hindrance to progress. As someone who is anxious to see a promising technology come to fruition, you should be joining those of us who are frustrated by Missling’s and the Board’s gross dereliction of duty to the shareholders.
By the way, how much money have you lost defending Missling? Be honest!
I had nakedvshort sells for lunch
Who is paying you to bash this company? Then I will tell you what I had for lunch and give you the scraps.
I am feeling better.Drank manuka tea withl lemon. I am here to counter people who are against novel treatments that could help my mom who has dementia.
What did you have for lunch?
Here is a person who posts day and night negative crap for years...should get a life. How do you have time for this?
The KEM Formal Concept Analysis is a very specific application of AI mixed with discrete statistics and data analysis.
AI is many things, but the media is not good at explaining the concepts involved and so a lot of people think of AI as magic or even terrifying.
There are 1.6 million people in the USA with schizophrenia and 3 million in Europe and 9 million in Asia with schizophrenia.
Anavex 3-71 can treat those people that currently have schizophrenia.
https://www.anavex.com/_files/ugd/850d88_80ed72201c1f4173a87f87a09470aa46.pdf
Good luck and GOD bless,
The week starts with a follow through bounce.... pushing past the first resistance zone around 3.55, hits 3.75 resistance, pulls back , now testing 3.50 support. Resistance overhead can still be 3.65 roll over, and tumble down, but resistance steps above that...looks like 3.80- 4.00 target area.
The current upwave/rally developing, early still, but 2 bounces are looking better than only one. Climbing back up 10 cent steps, looking for upwave target steps now, so long as support holds around 3.40.
I still don't think 3.25 will be the finished Bottom. So I'll be watching for resistance to cap somewhere, (3.85-4.00 area) and price to roll over and start tumbling again. But... today's follow through to make a real bounce, now 50 cents above the 3.25 pivot low, is starting to look like a real rally. Bearish bias is changed to neutral for me now.
Let's see how tomorrow goes and the response from shorts and traders. One can look at the larger downwave from , let's say 6.75 to the 3.25 Bottom, a drop of 3.50.... If we saw a fib retrace 50%, we're looking for a rally to retest 5.00 before becoming serious as a possible Bottom confirmation at 3.25. I.e. several more rally waves needed to start seeing a trend change and rally recovery. There will be good clues to observe now along the way, but a lot more chart watching to do from here.
“ With the conditional approval, I would have every patient have treatment results reported in a Phase 4 and that too could be the basis for making the conditional approval into a full approval.”
Especially is you apply AI to the process which Anavex has done for many years. I dont think the KEM analysis we use is as powerful as the latest AI but then again what do I know.
Anyway, LETS DO THIS!
“Trust AVXL”. Is this your new lie for Covid to sucker in your dupes?
I did buy shares in this remarkable c I many today..wow great price for me
These bashers will be at it tomorrow and if I am home sick I will out post these losers.
We have a bunch of losers attacking a company that could help your grand parents. Maybe it is one person with 6 aliases in a cubicle in miami.
And nobody is interested In reading your posts ..only your handlers.
Karuna Therapeutics completed two phase 3 studies, with larger enrollments, Anavex is still in POC stage with tiny study. For anavex to reach phase 3 stage, it will take decade or more, no one is interested in buying this POS.
News would be great. Approvals are essential. News has a short shelf life. Approvals make the company.
I get that the SP sucks. I chose to pay off my margin. Not what I wanted to do. That was better than selling shares at these prices.
That is 37 billion net worth. Stealing money from investors. What a joke this market is. Pump and dump. Any bio that has positive news gets the short selling program. I have the software that codes those shares. The billionaire hires all these short bashers who post here 24/7. Then they act like tough guys over the internet.
Let me naked short sell the stock then only have to pay a fine after collecting millions. What co. Do you think I am talking about? The director only is worth e 7 billion and is never satisfied and wants more.
Really? That's the best you got?
News? News? What News? We don't need any stinking news. We have Dr Missling.
The blood has drained from .y hands LTB
They are not in Biogen board!
Hunh
It's only 1% of the population
Asked by another basher like you.
You do realize that he was asked for his opinion and gave it.
The rest of your rant was your opinion based on nothing.
Anavex 3-71 (formerly known as AF710b)
Why didn't you post this negative rant before the results came out about trial sites and not going for the gold standard probably because you help your buddies after the fact to get some leftovers to sell.
Of course you failed to mention that they have a parkinsons readout in 2 months. Just coincidence Mr. Doc
Lots of naked short sales helped all the usual sort sellers. The short sale a to b program they run for all the bios usually lasts for 2 or 3 days. I will wait to get any dhares
Results are not good. I never understood why they did a 12 week trial with clinical endpoints rather than a smaller one-year or longer true P2 trial (I get that they did not have resources for a reasonably sized 18 month trial). Calling it a 2/3 for a 12 week trial was sketchy. As with many other small companies they went for cheap over quality -- they allowed a clinical diagnosis of probable AD (rather than PET or CSF proven), guaranteeing many misdiagnoses. This was further compounded by going with numerous non-neurology research sites (wonder if any were also BIVI sites; misdiagnosis rate by non-neuro is about 30% - though still 20% by neurologists compared to the gold standard tests). Perhaps the drug has some efficacy as mild AD patients with less misdiagnosis (ptau217/tTau ratio is almost as good as PET) showed ok 12 week data for ADAS-Cog 11 but with post-hoc analysis and multiplicity this could be a fluke. They did show that they can carry the higher dose forward. They need to raise a lot of funds so punishing dilution will come soon in order to finance a proper 18 month P3 that won't read out until 2027 at the earliest
I always enjoy your posts. When they do announce that they have filed the price of avxl will be much higher.
So, go avxl, by your review marks, this isn't the Anavex MB?
I thought this was the ANAVEX board!
I believe if the regulators would pay attention to the Hippocratic Oath they would approve drugs, like those Anavex has in trial, for broad use, but insist on conformational trials to maintain them on the market. I believe it's clear that patients either see benefit, or are no worse, in essentially all indications the drugs have been tried on. If something better than that were available, it would be approved, but it's not.
To me, a conditional approval is far superior to taking years, perhaps even a decade and hundreds of millions to run further trials while millions go untreated. With the conditional approval, I would have every patient have treatment results reported in a Phase 4 and that too could be the basis for making the conditional approval into a full approval.
I hate to continue saying it, but I believe the regulators should be far more pro-active. They should be looking into trials while they're underway and if they clearly see benefits, do conditional approvals immediately. In most cases this probably would cut off perhaps 5 years and a great deal of the cost of clinical trials and have the potential of saving many lives. I believe that benefits seen in most Phase 2 trials should be sufficient to see such benefits, and a million pages or more to prove it is ridiculous if the regulators could pro-actively speak with clinicians, patients, the DSMB, etc. and make a decision for themselves. If they don't wish to call them Conditional Approvals, call them EUA's. the point is not taking decades to take a product from preclinical development to availability to the patient. They did it for Covid 19, for the person with other deadly diseases, like pancreatic cancer, it's just as important to make miraculous products available in months, not decades.
Gary
Of course one of the things they'll 'improve' is the trial duration; 12 week data was never going to be accepted for an NDA. As the PR says, next step is an 18 month study of confirmed early AD patients.
I had to give you a thumbs up boi, even though I dont read his/her posts anymore, because you speak the truth.
Anavex 3-71 in New Schizophrenia Trials
Of course, blarcamesine against Alzheimer's is the major target for Anavex. But be aware of the company's new trials of Anavex 3-71 to safely and effectively treat patients with schizophrenia:
I am really getting tired of your bad faith arguments, especially considering you just claimed to have bought more AVXL.
A new statistical analysis by Anavex of the same underlying data does not represent cherry picking the data. And its dosed arm of 338 is significantly greater than a post hoc subset of 90.
Furthermore, in light of the emerging FDA approach to early AD trials, Anavex is simply using the ADAS-Cog endpoint as its sole basis for seeking FDA approval. This puts the company in an excellent position to file an NDA to go along with its regulatory progress with the EU, since the gatekeeping p value reverts to .05, which has been easily met by the 2b/3 AD cognitive p value of .0226.
And the reason I accuse you of bad faith is I know you understand all this, yet continue to post your BS.
Deeppockets21
Anavex's blarcamesine is in stage 4 right now concerning approval for treating Alzheimer's disease (see slide 13)
Look at slides 18 through 26 inclusive regarding Anavex's blarcamesine for the treatment of Alzheimer's disease.
https://www.anavex.com/_files/ugd/850d88_80ed72201c1f4173a87f87a09470aa46.pdf
Good luck and GOD bless,
Followers
|
1073
|
Posters
|
|
Posts (Today)
|
6
|
Posts (Total)
|
464004
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |